Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.54 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217587 | 1.00 | ALOX12 (1.00) | ALOX12ALOX15CYP19A1ALOX15BIDO1 | |
| SCHEMBL678222 | 0.88 | ALOX12 (0.79) | ALOX12ALOX15CYP19A1ALOX15B | |
| SCHEMBL133012 | 0.88 | ALOX12 (0.79) | ALOX12ALOX15CYP19A1ALOX15B | |
| SCHEMBL16152440 | 0.86 | ALOX12 (0.75) | ALOX12ALOX15CYP19A1 | |
| SCHEMBL5797926 | 0.86 | ALOX12 (0.75) | ALOX12ALOX15CYP19A1 | |
| SCHEMBL131543 | 0.86 | ALOX12 (0.75) | ALOX12ALOX15CYP19A1 | |
| SCHEMBL30951649 | 0.85 | ALOX12 (0.73) | ALOX12ALOX15CYP19A1 | |
| SCHEMBL13090337 | 0.85 | ALOX12 (0.74) | ALOX12ALOX15CYP19A1 | |
| SCHEMBL3357784 | 0.84 | ALOX12 (1.00) | ALOX12ALOX15CYP19A1 | |
| SCHEMBL4806201 | 0.81 | CYP19A1 (0.77) | ALOX12CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | claimed |
| EP-1189897-A1 | ISOFLAVONE METABOLITES | G.J. Consultants Pty Ltd (AU) | 2002-03-27 | — | — | EP | claimed |
| WO-2000066576-A1 | ISOFLAVONE METABOLITES | G.J. CONSULTANTS PTY LTD (AU) | 2000-11-09 | — | — | WO | claimed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | disclosed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240355451-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | NESTLE SA (CH) | 2024-10-24 | — | — | US | disclosed |
| EP-4391834-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240101791-A1 | POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024059282-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023025722-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2023-03-02 | — | — | WO | disclosed |
| EP-1189897-B1 | ISOFLAVONE METABOLITES | G J CONSULTANTS PTY LTD (AU) | 2006-10-18 | — | — | EP | disclosed |
| EP-1670485-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670484-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| US-7056952-B1 | for example, 3'-hydroxy-dihydrodaidzein, 5-hydroxy-O-demethylangolesin; for treating hormone dependent conditions and other diseases and disorders; anticarcinogenic agents | G.J. CONSULTANTS PTY. LTD. (AU) | 2006-06-06 | — | — | US | disclosed |
| US-20050222248-A1 | Isoflavone metabolites | JOANNOU GEORGE E | 2005-10-06 | — | — | US | disclosed |
| WO-2005034960-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| WO-2005032559-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | NOS2, NOS3, NOS1 | ALOX12 191/4885ALOX15 206/4885CYP19A1 357/4885 |
| US-20050222248-A1 | Isoflavone metabolites | CYP19A1, ESR1, CYP21A2 | ALOX12 2799/4885ALOX15 2916/4885CYP19A1 1/4885 |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | NOS2, NOS1, NOS3 | ALOX12 218/4885ALOX15 265/4885CYP19A1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.